Search Results
Your search for ,OUr matches 10724 pages
Showing 1 - 50ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
ASCO has announced a collaboration with Ryght AI aimed at accelerating the identification and activation of research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study, a clinical trial evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. The...
Behind the Scenes of the 2026 ASCO Annual Meeting
The ASCO Annual Meeting is one of the largest and most impactful oncology conferences of the year, featuring practice-changing data, state-of-the-art updates, developmental therapeutics, global issues, and more. The 2026 meeting is expected to showcase paradigm-shifting science, presentations from...
Local Radiotherapy May Help Control Oligometastatic Breast Cancer
Local radiotherapy may help control disease spread in patients with oligometastatic breast cancer, according to findings from the OLIGOMA trial presented during the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026; Abstract 5611). “Currently, patients with oligometastatic ...
Radiotherapy for Prostate Cancer: HERMES Trial Compares Two and Five Fractions
Two larger doses of radiotherapy for prostate cancer caused no additional side effects compared to the standard five doses of radiotherapy, according to results from the HERMES trial presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the...
Better Together: The Case for True Physician-AP Partnership in Oncology
At 8 am, the infusion chairs are already full. The oncologist is in a room seeing a new patient consult, the pharmacist is adjusting doses based on new lab values, and the advanced practitioner (AP) is sitting with a patient—reviewing symptoms, discussing how to manage treatment side effects, and ...
Survival Among Patients Treated in Community Oncology Settings Compared With National Benchmarks From SEER Database
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) when treated at community oncology practices participating in the Flatiron Health Research Network had better or comparable survival compared with national benchmark survival estimates generated by the...
Facing a Year Ahead of Unprecedented Opportunities—and Challenges
This year has marked unprecedented progress against cancer—as well as challenges. According to findings in the American Cancer Society’s Cancer Statistics, 2026 report, the 5-year relative survival rate for all cancers combined has reached a milestone of 70% for individuals diagnosed between 2015...
ASCO Congratulates 2026 Special Award Recipients
ASCO and Conquer Cancer, the ASCO Foundation, are proud to celebrate a distinguished group of individuals at the 2026 ASCO Annual Meeting. The Society will present its highest honors to researchers, educators, patient advocates, and global leaders for their career-defining excellence and tremendous ...
Four Ways AI Is Transforming Patient Care—and What Lies Ahead
During her Presidential address at the 2025 ASCO Annual Meeting, Robin T. Zon, MD, FACP, FASCO, assessed how artificial intelligence (AI) is driving knowledge into action in the field of oncology, and acknowledged that “we are now at the crossroads of long-imagined possibilities and actionable...
Early Myocarditis After Immune Checkpoint Inhibitors Signals Elevated Mortality Risk
Early onset of immune checkpoint inhibitor (ICI)–related myocarditis is associated with increased mortality risk, as is the presence of concurrent major adverse cardiac events, according to results presented in a poster and at a press briefing during the 2026 American Association for Cancer...
Uniting Science, Practice, and Purpose for Better Cancer Care
Growing up as an American in Mexico City, I couldn’t have grasped how that upbringing would eventually shape my professional identity. While a career in oncology was far from my mind then, that cross-cultural foundation deeply influenced my approach to medicine and my leadership as ASCO’s 62nd...
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Although treatment advances have increased the 5-year relative survival rates across all age groups, including a 15% increase for adolescents and young adults ages 15 to 39 years,1 it varies widely for some cancers among AYAs who are diagnosed with cancer. For example, AYAs have substantially worse ...
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
In two complementary preclinical studies published in Blood, investigators reported that mezigdomide, a cereblon E3 ligase modulator, may help overcome T-cell dysfunction in multiple myeloma, thereby enhancing the activity of BCMA-directed CAR T-cell and bispecific T-cell engager therapies. These...
GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers
Real-world data suggest that GLP-1 receptor agonists (RAs) may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers, according to findings to be presented at the 2026 ASCO Annual Meeting (Abstract 3143). GLP-1 receptor expression ...
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
Researchers have developed a novel diagnostics tool to detect gene fusions in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with greater sensitivity than standard detection algorithms, according to findings from a study published in The Journal of Molecular Diagnostics. The researchers...
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy...
Study Shows Potential Missing Patient Information in SEER Database
A significant number of patients with cancer—particularly those with more advanced disease who are more likely to receive care at community hospitals, safety net hospitals, and rural medical centers—may have incomplete case information in the Surveillance, Epidemiology, and End Results (SEER)...
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
A new meta-analysis published by Costa et al in JNCCN—Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief...
Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade
A new study shows that cases of stage IV breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published by Avila et al in JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly from 9.5...
How Conquering Cancer Is a Team Effort
After finishing her academic studies, Dr. Mittendorf enlisted in the U.S. Air Force—an experience that would propel her into the field of oncology. “My second day on active duty was September 11, 2001,” said Dr. Mittendorf. “I was an attending surgeon at Walter Reed Army Medical Center (now called...
Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer
Final overall survival results from the phase III ROSELLA trial showed a statistically and clinically significant survival benefit with the selective glucocorticoid receptor antagonist relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer....
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?
A systematic review and meta-analysis published in JAMA Network Open found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers. According to Inoue et al, this association appeared to be particularly pronounced in non–small cell lung...
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonged overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer...
Inherited Long Telomeres May Increase the Risk of Lymphoid Cancers
Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins have identified a genetic syndrome in which unusually long telomeres—the protective caps at the ends of chromosomes—allow immune cells to remain biologically “younger” for longer than normal, predisposing ...
New Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma
A clinical whole-genome sequencing test for patients with multiple myeloma, JAYseq, has been launched at the Translational Genomics Research Institute (TGen). “The launch of JAYseq represents a meaningful step in oncology testing, one that allows physicians to make a more precise treatment...
First Virtual Cancer Clinic to Receive ASCO Certified Status
ASCO has certified its first virtual cancer clinic from Color, a company that owns and operates a nationwide, oncologist-led Virtual Cancer Clinic, serving employer, union, health plan, and public sector populations. The ASCO Certified status indicates that the virtual practice meets a high set of...
Patient Care Is Not What We Do, But What Patients Perceive
In modern health care, patient care is often defined by clinical actions such as diagnoses made, treatments delivered, and protocols followed. Clinicians are trained to prioritize technical accuracy, evidence-based interventions, and measurable outcomes. However, an equally critical and often...
Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book
ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book. Dr. Hsu is a Professor of Clinical Medicine at the University of California, San Francisco (UCSF), where he has served in numerous educational leadership roles. Since 2018,...
National Academy of Medicine Recognizes 100 Newly Elected Members
Overview of Member Election Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current members through a process that acknowledges individuals who have made major...
Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures
Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occurring in low- and middle-income countries.1 Delays in obtaining an accurate diagnosis,...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
LLM Tool Significantly Reduces Participant Screening Burdens, Improves Enrollment for Phase III Trial in Polycythemia Vera
Synapsis AI, a medically trained, large language model (LLM)–based end-to-end system, reduced the time and effort needed to screen for eligible patients to participate in a randomized, interventional phase III clinical trial in patients with polycythemia vera (PV). Use of Synapsis AI also led to...
High YAP1 Expression Leads to Chemotherapy Resistance, Relapse in Treated SCLC
Expression of the YAP1 protein following treatment with chemotherapy is associated with the development of treatment resistance and cancer relapse in patients with small cell lung cancer (SCLC), according to findings from an analysis published in Journal of Thoracic Oncology. The researchers...
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alone. Interim results from the CLIMATE study found post-orchiectomy plasma miR-371a-3p (miR-371), a...
Breast Density Reduction: Endoxifen vs Tamoxifen
Low doses of the investigational agent endoxifen reduced breast density to the same extent as the standard treatment tamoxifen, with fewer adverse events, according to results from the KARISMA study, a proof-of-principle, dose-determining, double-blinded, randomized, placebo-controlled trial. These ...
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
Investigators used data from the Surveillance, Epidemiology, and End Results (SEER) database to analyze trends in multiple myeloma mortality in the United States from 1975 to 2023. Their findings were published in Oncotarget. The study was led by first and corresponding author Navkirat Kahlon, MD,...
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by...
Four-Drug Regimen Induces High Complete Response Rate in Early-Stage Classical Hodgkin Lymphoma
High objective response and complete response rates were observed with treatment with brentuximab vedotin and nivolumab in combination with doxorubicin and dacarbazine chemotherapy in patients with early-stage classical Hodgkin lymphoma, according to the results of a phase II trial published in...
Melanoma: Gut Microbiome May Help Predict Recurrence After Immunotherapy
Gut bacterial markers may be able to predict recurrence in patients with high-risk melanoma receiving adjuvant immune checkpoint inhibition, according to study findings published in Cell. “Our study identified for the first time gut bacterial types that can serve as markers of increased recurrence ...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
Can Pesticide Exposure Increase Early-Onset Colorectal Cancer Risk?
A new study has identified for the first time the exposome footprint—the set of environmental and lifestyle exposures—for colorectal cancer occurring in patients younger than age 50 through epigenetic signatures. By comparatively analyzing DNA methylation patterns in patients under and over 50, the ...
MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy and maximal transurethral resection may be safe and feasible in patients with muscle-invasive bladder cancer (MIBC), allowing many patients to potentially avoid cystectomy, according to the results of a...
Tracking Biological Age Changes Gives Insights Into Cancer Prognosis
Face aging rate, a measure of changes in biological age over time, could serve as a noninvasive prognostic biomarker for determining outcomes in patients with cancer, according to the results of a study published in Nature Communications. “Deriving a Face Aging Rate from multiple, routine facial...
Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality
Long-term exposure to air pollution significantly increases both the risk of developing cancer and the likelihood of dying from the disease, according to a new global evidence report released by the Union for International Cancer Control (UICC), titled Clean air in cancer control: An overview of...
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up. In mid-April, Revolution Medicines announced positive results from its phase III RASolute 302 clinical trial of daraxonrasib, an ...
Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants
Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5039). The researchers...
ACP Issues Controversial New Breast Cancer Screening Guidelines
New guidance from the American College of Physicians (ACP) says all average-risk females between ages 50 to 74 should receive biennial screening mammography for breast cancer, and that females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the...
GLP-1 RAs May Reduce Mortality In Some Patients With Colorectal Cancer and Comorbid Obesity: Real-World Outcomes
Colon cancer is among the leading causes of cancer-related morbidity and mortality worldwide, with alarming increases in incidence and mortality among younger adults. Although the exact causes of these increases are unknown, lifestyle, including poor diets, sedentary habits, smoking, and alcohol...
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in BRCA/ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 and/or ATM alterations.1...
Perioperative Pembrolizumab in Localized Colorectal Cancer With dMMR/MSI
In a French phase II study (IMHOTEP) reported in the Journal of Clinical Oncology, de la Fouchardière et al found that perioperative pembrolizumab was active in previously untreated resectable localized colorectal cancer with mismatch repair deficiency (dMMR)/microsatellite instability (MSI). Study ...
